Ingrezza® (valbenazine)
for Tardive Dyskinesia
Ingrezza (valbenazine) is used to treat tardive dyskinesia (TD) and chorea associated with Huntington's disease, both of which are movement disorders. It works by decreasing dopamine levels in the nerve endings of the brain, helping to control body movements. Ingrezza is a VMAT2 inhibitor, meaning it inhibits the vesicular monoamine transporter 2 (VMAT2) in neurons, which plays a key role in regulating neurotransmitter release.
